---
title: "Explainable Clinician-Supervised AI Framework (CHAPERONE-CKM) for CKM Population Health: Synthetic"
id: "medrxiv-6-explainable-clinician-supervised-artificial-intelligence-as-an-implementation"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-6-explainable-clinician-supervised-artificial-intelligence-as-an-implementation"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.17.26360643v1?rss=1"
published_at: "2026-08-19T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Explainable Clinician-Supervised AI Framework (CHAPERONE-CKM) for CKM Population Health: Synthetic
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-6-explainable-clinician-supervised-artificial-intelligence-as-an-implementation
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.17.26360643v1?rss=1)
- **Published At:** 2026-08-19T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study presents the **CHAPERONE-CKM** framework: an explainable, clinician-supervised artificial intelligence implementation framework aimed at managing cardiovascular-kidney-metabolic (CKM) population health. - Validation used a reproducible synthetic cohort of 10,090 simulated patients with 128 variables spanning demographics, laboratory, imaging, treatments, and healthcare utilization across the CKM continuum. - Synthetic data generation was separated from framework evaluation via probabilistic modeling and independent validation to reduce deterministic relationships and protect privacy. - The framework produced CKM stage assignments, implementation priorities, clinician-readable rationales, multidisciplinary referral pathways, and guideline-directed therapy prompts. - Evaluation focused on implementation readiness domains: consistency, calibration, subgroup stability, fairness, workflow simulation, and explainability rather than treating traditional performance metrics as proof of clinical effectiveness. - In the synthetic population, condition prevalences included diabetes (52%), hypertension (65%), chronic kidney disease (20%), heart failure (32%), and prior CKM hospitalization (27%). - The framework demonstrated stable internal behavior across demographic and clinical subgroups, favorable calibration, and biologically plausible prioritization of advanced CKM disease. - Workflow simulations suggested earlier identification of patients for multidisciplinary review, therapy optimization, and coordinated care compared with reactive workflows. - Authors emphasize these results are an early translational milestone in a synthetic environment and explicitly state this is not clinical validation. - The report calls for external validation, prospective implementation studies, and integration with Learning Health Systems to assess effects on care delivery, equity, and value-based outcomes. - The complete software framework is proprietary; synthetic data specifications and analytical workflows will be made available on reasonable request while protecting proprietary algorithms. - Ethical oversight and approvals are reported: broader CHAPERONE-CKM study reviewed and approved by Elemental Independent Review Board; Phase Ib used synthetic records and did not require separate consent. - No competing interests were declared by the authors in the preprint.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=PiUBAh3.oT3Scb4sRADaRiJvs7momknnZRVryiIbCNM-1787181684.9776912-1.2.1.1-0hGYgYKUsL8s.grtNRI8Hgr4VLlRP9HvaTr8kh6W4iChuIHu8oL6zcLqmIfakK9g) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.17.26360643v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Explainable Clinician-Supervised Artificial Intelligence as an Implementation Framework for Cardiovascular-Kidney-Metabolic Population Health: Synthetic Data Validation of the CHAPERONE-CKM Framework Aditya Vijay, Navin Govind, Arjun Moorthy, [ View ORCID Profile](http://orcid.org/0000-0002-3997-8335)Patrick Dunn, Zaki Lababidi, Sun Jones, [ View ORCID Profile](http://orcid.org/0000-0003-0319-6240)Marcus Ståhlberg, Samer Ibrahim, Keyvan Koochek, [ View ORCID Profile](http://orcid.org/0000-0002-3012-9943)Kevin S Shah, Randal Schulhauser, Edgar V. Lerma, Lakshmi Nair, Jordi Livi, [ View ORCID Profile](http://orcid.org/0000-0001-5254-4067)Dinesh K. Kalra, Devendra Wadwekar, Wes Gulllett, [ View ORCID Profile](http://orcid.org/0000-0002-0919-9736)Krishnaswami Vijayaraghavan doi: https://doi.org/10.64898/2026.08.17.26360643 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Aditya Vijay 1 Aventyn Inc; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Aditya%2BVijay%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Vijay%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAditya%2BVijay%2B) Navin Govind 1 Aventyn Inc; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Navin%2BGovind%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Govind%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANavin%2BGovind%2B) Arjun Moorthy 2 The George Washington University School of Medicine and Health Sciences; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Arjun%2BMoorthy%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Moorthy%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AArjun%2BMoorthy%2B) Patrick Dunn 3 American Heart Association Georgia; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Patrick%2BDunn%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Dunn%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APatrick%2BDunn%2B) * [ORCID record for Patrick Dunn](http://orcid.org/0000-0002-3997-8335 "Open in new tab") Zaki Lababidi 4 Mercy Gilbert Medical Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Zaki%2BLababidi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lababidi%20Z&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AZaki%2BLababidi%2B) Sun Jones 5 University of Phoenix - Phoenix Main Campus; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sun%2BJones%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Jones%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASun%2BJones%2B) Marcus Ståhlberg 6 Karolinska Institutet, Karolinska Uiniversity Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Marcus%2BSt%C3%A5hlberg%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=St%C3%A5hlberg%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMarcus%2BSt%25C3%25A5hlberg%2B) * [ORCID record for Marcus Ståhlberg](http://orcid.org/0000-0003-0319-6240 "Open in new tab") Samer Ibrahim 7 Mayo Clinic Arizona; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Samer%2BIbrahim%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ibrahim%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASamer%2BIbrahim%2B) Keyvan Koochek 8 HonorHealth; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Keyvan%2BKoochek%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Koochek%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKeyvan%2BKoochek%2B) Kevin S Shah 9 MemorialCare Heart & Vascular; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kevin%2BS%2BShah%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Shah%20KS&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKevin%2BS%2BShah%2B) * [ORCID record for Kevin S Shah](http://orcid.org/0000-0002-3012-9943 "Open in new tab") Randal Schulhauser 10 Schulhauser & Associates, Phoenix, AZ, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Randal%2BSchulhauser%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Schulhauser%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARandal%2BSchulhauser%2B) Edgar V. Lerma 11 Advocate Christ Medical Center, University of Illinois at Chicago; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Edgar%2BV.%2BLerma%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lerma%20EV&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEdgar%2BV.%2BLerma%2B) Lakshmi Nair 12 Arizona State University; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lakshmi%2BNair%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nair%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALakshmi%2BNair%2B) Jordi Livi 8 HonorHealth; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jordi%2BLivi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Livi%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJordi%2BLivi%2B) Dinesh K. Kalra 13 University of Louisville; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Dinesh%2BK.%2BKalra%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kalra%20DK&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADinesh%2BK.%2BKalra%2B) * [ORCID record for Dinesh K. Kalra](http://orcid.org/0000-0001-5254-4067 "Open in new tab") Devendra Wadwekar 14 East Valley Diabetes and Endocrinology; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Devendra%2BWadwekar%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wadwekar%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADevendra%2BWadwekar%2B) Wes Gulllett 15 Weartech Applied Research Center; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Wes%2BGulllett%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Gulllett%20W&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AWes%2BGulllett%2B) Krishnaswami Vijayaraghavan 16 The University of Arizona College of Medicine Phoenix * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Krishnaswami%2BVijayaraghavan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Vijayaraghavan%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKrishnaswami%2BVijayaraghavan%2B) * [ORCID record for Krishnaswami Vijayaraghavan](http://orcid.org/0000-0002-0919-9736 "Open in new tab") * For correspondence: kvijaymd@gmail.com * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.17.26360643v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1281502/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.17.26360643v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1281502/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.17.26360643v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1281502/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.17.26360643v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1281502/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.17.26360643v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1281502/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Abstract Background: Cardiovascular-kidney-metabolic (CKM) syndrome is an increasingly prevalent multisystem condition associated with morbidity, fragmented care, recurrent hospitalization, and rising healthcare costs. While cardiovascular risk models estimate future disease risk, fewer frameworks support multidisciplinary CKM care, clinician decision-making, and population health management. Synthetic data environments can assess implementation readiness while preserving privacy. Methods: We validated the explainable, clinician-supervised CHAPERONE-CKM framework using a reproducible synthetic cohort of 10,090 simulated patients with 128 demographic, laboratory, imaging, treatment, and healthcare utilization variables across the CKM continuum. Synthetic data generation was separated from framework evaluation through probabilistic modeling and independent validation to reduce deterministic relationships. The framework generated CKM stage assignments, implementation priorities, clinician-readable rationales, multidisciplinary referral pathways, and guideline-directed therapy prompts. Evaluation focused on implementation readiness, consistency, calibration, subgroup stability, fairness, workflow simulation, and explainability. Results: The synthetic population represented CKM-related conditions including diabetes (52%), hypertension (65%), chronic kidney disease (20%), heart failure (32%), and prior CKM hospitalization (27%). The framework showed stable internal behavior across demographic and clinical subgroups, favorable calibration, and biologically plausible prioritization of advanced CKM disease. Workflow simulations suggested earlier identification of patients suitable for multidisciplinary review, therapy optimization, and coordinated care compared with reactive workflows. Traditional performance metrics supported framework behavior but were treated as secondary evidence rather than proof of clinical effectiveness. Conclusions: In a synthetic validation environment, the CHAPERONE-CKM framework demonstrated implementation readiness, transparent decision pathways, and compatibility with multidisciplinary CKM population health management. These findings are an early translational milestone, not clinical validation, and support external validation, prospective implementation studies, and Learning Health System integration to assess effects on care delivery, equity, and value-based outcomes. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial NCT07403669 ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The broader CHAPERONE-CKM study was conducted in accordance with the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice guidelines, and applicable institutional and regulatory requirements. The protocol was reviewed and approved by Elemental Independent Review Board, 401 Ryland St., STE 200-A, Reno, NV 89502, USA; OHRO Submission Number 370344. Written informed consent was obtained from participants before completion of Phase Ia procedures. For Phase Ib, all records were synthetic and contained no identifiable human data; therefore, separate informed consent was not required. ClinicalTrials.gov identifier: [NCT07403669](https://www.medrxiv.org/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT07403669&atom=%2Fmedrxiv%2Fearly%2F2026%2F08%2F19%2F2026.08.17.26360643.atom). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The complete software framework and implementation engine constitute proprietary intellectual property. Synthetic data specifications, variable definitions, and analytical workflows sufficient to reproduce the published analyses will be made available upon reasonable request while protecting proprietary algorithms. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.17.26360643v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.17.26355624v1 "Olfactory Dysfunction in Primary Ciliary Dyskinesia: A Systematic Review and Meta-analysis")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.18.26360601v1 "Detecting early loss of kidney function in a Sri Lankan cohort study of working age adults") Posted August 19, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.17.26360643v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/19/2026.08.17.26360643.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.17.26360643v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/19/2026.08.17.26360643.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Explainable Clinician-Supervised Artificial Intelligence as an Implementation Framework for Cardiovascular-Kidney-Metabolic Population Health: Synthetic Data Validation of the CHAPERONE-CKM Framework Aditya Vijay, Navin Govind, Arjun Moorthy, Patrick Dunn, Zaki Lababidi, Sun Jones, Marcus Ståhlberg, Samer Ibrahim, Keyvan Koochek, Kevin S Shah, Randal Schulhauser, Edgar V. Lerma, Lakshmi Nair, Jordi Livi, Dinesh K. Kalra, Devendra Wadwekar, Wes Gulllett, Krishnaswami Vijayaraghavan medRxiv 2026.08.17.26360643; doi: https://doi.org/10.64898/2026.08.17.26360643 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https:
## Related Clinical Research

- [Infection Does Not Impair Decongestion or Short-Term Kidney Outcomes in Cardiorenal Syndrome Type 1](https://medichelpline.com/clinical-feed/plos-one-11-impact-of-infection-on-decongestion-and-kidney-outcomes-in-patients-with.md)
- [Boost Potassium as well as Lower Sodium for Better Blood Pressure Control](https://medichelpline.com/clinical-feed/medical-news-today-0-for-better-blood-pressure-control-don-t-just-lower-salt-also-boost-potassium.md)
- [Beta-blocker continuation during prolonged dobutamine in heart transplant candidates: competing-ri](https://medichelpline.com/clinical-feed/plos-one-17-continuation-of-beta-blockers-during-prolonged-dobutamine-infusion-in-heart.md)
- [Sex‐Specific Outcomes and Treatment Responses in Elderly Patients With Heart Failure With Preserved Ejection Fraction: A Comprehensive Single‐Center Retrospective Study](https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-10-sex-specific-outcomes-and-treatment-responses-in-elderly-patients-with-heart.md)
- [Adherence to Medications, Lifestyle Advice, and Self‑Monitoring for Type 2 Diabetes and Hypertensi](https://medichelpline.com/clinical-feed/plos-medicine-0-adherence-to-medications-lifestyle-advice-and-self-monitoring-for-type-2.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.